Spravato is the only drug derived from ketamine that is FDA-approved to treat a psychiatric condition. Some health clinics ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.

Spravato has a list of potential side effects, including disassociation, dizziness, nausea, sedation, vertigo, decreased feeling or sensitivity, anxiety, lethargy, increased blood pressure ...

anxiety, vomiting, feeling drunk, increased blood pressure, and sedation. No new safety signals were identified in the trial. Spravato is classified as a Schedule III controlled substance and is ...

major depressive disorder and social phobia being the most common anxiety disorders,” states ADAA. To date, Spravato has been administered to over 140,000 patients globally. 1 “For more than six years ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

They might be grappling with unresolved trauma or ch We specialize in breakthrough therapies like ketamine, TMS, and Spravato for depression, anxiety, PTSD, and mood disorders. Certified in ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...